OTCMKTS:IDXG Interpace Biosciences Q2 2026 Earnings Report $6.39 0.00 (0.00%) As of 09/30/2026 02:15 PM Eastern ProfileEarnings History Interpace Biosciences EPS ResultsActual EPS$0.05Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInterpace Biosciences Revenue ResultsActual Revenue$9.13 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInterpace Biosciences Announcement DetailsQuarterQ2 2026Date8/10/2026TimeAfter Market ClosesConference Call DateMonday, August 10, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Interpace Biosciences Earnings HeadlinesPDI Gold Limited Issues Comprehensive 2026 Annual Information FormSeptember 29 at 7:51 PM | tipranks.comPDI Gold Transforms into Producer After Robex Merger and Shifts to Calendar-Year ReportingSeptember 29 at 7:51 PM | tipranks.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 1 at 1:00 AM | Weiss Ratings (Ad)Circuit Breaker Halts Continuous Trading in TAPDI Oksijen Shares on Borsa İstanbulSeptember 29 at 3:50 AM | tipranks.comMajor Insider Move Signals Growing Confidence in PIMCO DynamicSeptember 28 at 10:30 PM | tipranks.comBorsa Istanbul Halts TNZTP.E for Short Circuit-Breaker AuctionSeptember 28 at 6:31 AM | tipranks.comSee More Interpace Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Interpace Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Interpace Biosciences and other key companies, straight to your email. Email Address About Interpace BiosciencesInterpace Biosciences (OTCMKTS:IDXG) is a molecular diagnostics company focused on providing testing and pathology services that support the diagnosis and management of cancer and other complex diseases. The company’s tests are designed to help physicians assess disease risk, improve diagnostic confidence and guide treatment decisions. Its portfolio has included molecular tests for thyroid nodules, pancreatic cysts and gastrointestinal conditions. Key offerings include ThyGeNEXT and ThyraMIR for evaluating thyroid nodules, as well as PancraGEN and PanDNA for assessing pancreatic cysts. These products combine molecular analysis with clinical and pathology information to help distinguish potentially serious disease from conditions that may be monitored more conservatively. Interpace serves physicians, hospitals, laboratories and other health-care providers primarily in the United States through its laboratory and commercial operations. The company previously operated under the PDI name before adopting the Interpace Biosciences identity as its business became centered on molecular diagnostics and personalized medicine.View Interpace Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
